Compare Box Inc (BOX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs TG Therapeutics Inc — how do they compare? Box Inc trades at $32.33 (market cap $4.48B), while TG Therapeutics Inc trades at $48.26 (market cap $7.58B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Box Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| BOX | TGTX | |
|---|---|---|
Market Cap | $4.48B | $7.58B |
Sector | Technology | Health |
52-Week High | $33.60 | $59.06 |
52-Week Low | $21.37 | $26.94 |
Enterprise Value | $5.03B | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX trades at $32.33, down 3.78% today, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth to $1.09B in 2025 and net income of $244.62M, though valuation metrics like P/E of 51.3 appear elevated. Recent news highlights Box's AI content management capabilities, including a partnership with Quintas Energy announced July 30, 2026.
The stock offers upside to the $37 consensus price target, supported by 60.7% analyst buy ratings. Key risks include high valuation multiples and competitive pressures in cloud content management. Positive cash flow trends and earnings beats in three of the last four quarters provide fundamental support for continued growth.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
